Differential effect of zoledronic acid on human vascular smooth muscle cells

Hassan Albadawi, Mounir J. Haurani, Rahmi Oklu, Jordan P. Trubiano, Peter J. Laub, Hyung Jin Yoo, Michael T. Watkins

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: The activation of human vascular smooth muscle cell proliferation, adhesion and migration is essential for intimal hyperplasia formation. These experiments were designed to test whether zoledronic acid (ZA) would modulate indices of human smooth muscle cell activation, exert differential effects on proliferating versus quiescent cells, and determine whether these effects were dependent on GTPase binding proteins prenylation. ZA was chosen for testing in these experiments because it is clinically used in humans with cancer, and has been shown to modulate rat smooth muscle cell proliferation and migration. Methods: Human aortic smooth muscle cells (HASMC) were cultured under either proliferating or growth arrest (quiescent) conditions in the presence or absence of ZA for 48 hours, whereupon the effect of ZA on HASMC proliferation, cellular viability, metabolic activity, and membrane integrity were compared. In addition, the effect of ZA on adhesion and migration were assessed in proliferating cells. The effect of increased concentration of ZA on the mevalonate pathway and genomic/cellular stress related poly-adenosine diphosphate ribose polymerase enzyme activity were assessed using the relative prenylation of Rap-1A/B protein and the formation of poly adenosine diphosphate-ribosylated protein, respectively. Results: There was a dose dependent inhibition of cellular proliferation, adhesion and migration following ZA treatment. ZA treatment decreased indices of cellular viability and significantly increased membrane injury in proliferating versus quiescent cells. This was correlated with the appearance of unprenylated Rap-1A protein and dose dependent down regulation of activity. Conclusions: These data suggest that ZA is effective in inhibiting HASMC proliferation, adhesion, and migration, which coincide with the appearance of unprenylated RAP-1A/B protein, thereby suggesting that the mevalonate pathway may play a role in the inhibition of HASMC activation.

Original languageEnglish (US)
Pages (from-to)339-346
Number of pages8
JournalJournal of Surgical Research
Volume182
Issue number2
DOIs
StatePublished - Jun 15 2013
Externally publishedYes

Fingerprint

zoledronic acid
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cell Proliferation
Cell Movement
Mevalonic Acid
Cell Adhesion
Protein Prenylation
Tunica Intima
Poly Adenosine Diphosphate Ribose
Prenylation
Membranes
GTP Phosphohydrolases

Keywords

  • Bisphosphonates
  • Intimal hyperplasia
  • Vascular smooth muscle

ASJC Scopus subject areas

  • Surgery

Cite this

Differential effect of zoledronic acid on human vascular smooth muscle cells. / Albadawi, Hassan; Haurani, Mounir J.; Oklu, Rahmi; Trubiano, Jordan P.; Laub, Peter J.; Yoo, Hyung Jin; Watkins, Michael T.

In: Journal of Surgical Research, Vol. 182, No. 2, 15.06.2013, p. 339-346.

Research output: Contribution to journalArticle

Albadawi, Hassan ; Haurani, Mounir J. ; Oklu, Rahmi ; Trubiano, Jordan P. ; Laub, Peter J. ; Yoo, Hyung Jin ; Watkins, Michael T. / Differential effect of zoledronic acid on human vascular smooth muscle cells. In: Journal of Surgical Research. 2013 ; Vol. 182, No. 2. pp. 339-346.
@article{e786013047854b099df19e0ce444b427,
title = "Differential effect of zoledronic acid on human vascular smooth muscle cells",
abstract = "Introduction: The activation of human vascular smooth muscle cell proliferation, adhesion and migration is essential for intimal hyperplasia formation. These experiments were designed to test whether zoledronic acid (ZA) would modulate indices of human smooth muscle cell activation, exert differential effects on proliferating versus quiescent cells, and determine whether these effects were dependent on GTPase binding proteins prenylation. ZA was chosen for testing in these experiments because it is clinically used in humans with cancer, and has been shown to modulate rat smooth muscle cell proliferation and migration. Methods: Human aortic smooth muscle cells (HASMC) were cultured under either proliferating or growth arrest (quiescent) conditions in the presence or absence of ZA for 48 hours, whereupon the effect of ZA on HASMC proliferation, cellular viability, metabolic activity, and membrane integrity were compared. In addition, the effect of ZA on adhesion and migration were assessed in proliferating cells. The effect of increased concentration of ZA on the mevalonate pathway and genomic/cellular stress related poly-adenosine diphosphate ribose polymerase enzyme activity were assessed using the relative prenylation of Rap-1A/B protein and the formation of poly adenosine diphosphate-ribosylated protein, respectively. Results: There was a dose dependent inhibition of cellular proliferation, adhesion and migration following ZA treatment. ZA treatment decreased indices of cellular viability and significantly increased membrane injury in proliferating versus quiescent cells. This was correlated with the appearance of unprenylated Rap-1A protein and dose dependent down regulation of activity. Conclusions: These data suggest that ZA is effective in inhibiting HASMC proliferation, adhesion, and migration, which coincide with the appearance of unprenylated RAP-1A/B protein, thereby suggesting that the mevalonate pathway may play a role in the inhibition of HASMC activation.",
keywords = "Bisphosphonates, Intimal hyperplasia, Vascular smooth muscle",
author = "Hassan Albadawi and Haurani, {Mounir J.} and Rahmi Oklu and Trubiano, {Jordan P.} and Laub, {Peter J.} and Yoo, {Hyung Jin} and Watkins, {Michael T.}",
year = "2013",
month = "6",
day = "15",
doi = "10.1016/j.jss.2012.10.033",
language = "English (US)",
volume = "182",
pages = "339--346",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Differential effect of zoledronic acid on human vascular smooth muscle cells

AU - Albadawi, Hassan

AU - Haurani, Mounir J.

AU - Oklu, Rahmi

AU - Trubiano, Jordan P.

AU - Laub, Peter J.

AU - Yoo, Hyung Jin

AU - Watkins, Michael T.

PY - 2013/6/15

Y1 - 2013/6/15

N2 - Introduction: The activation of human vascular smooth muscle cell proliferation, adhesion and migration is essential for intimal hyperplasia formation. These experiments were designed to test whether zoledronic acid (ZA) would modulate indices of human smooth muscle cell activation, exert differential effects on proliferating versus quiescent cells, and determine whether these effects were dependent on GTPase binding proteins prenylation. ZA was chosen for testing in these experiments because it is clinically used in humans with cancer, and has been shown to modulate rat smooth muscle cell proliferation and migration. Methods: Human aortic smooth muscle cells (HASMC) were cultured under either proliferating or growth arrest (quiescent) conditions in the presence or absence of ZA for 48 hours, whereupon the effect of ZA on HASMC proliferation, cellular viability, metabolic activity, and membrane integrity were compared. In addition, the effect of ZA on adhesion and migration were assessed in proliferating cells. The effect of increased concentration of ZA on the mevalonate pathway and genomic/cellular stress related poly-adenosine diphosphate ribose polymerase enzyme activity were assessed using the relative prenylation of Rap-1A/B protein and the formation of poly adenosine diphosphate-ribosylated protein, respectively. Results: There was a dose dependent inhibition of cellular proliferation, adhesion and migration following ZA treatment. ZA treatment decreased indices of cellular viability and significantly increased membrane injury in proliferating versus quiescent cells. This was correlated with the appearance of unprenylated Rap-1A protein and dose dependent down regulation of activity. Conclusions: These data suggest that ZA is effective in inhibiting HASMC proliferation, adhesion, and migration, which coincide with the appearance of unprenylated RAP-1A/B protein, thereby suggesting that the mevalonate pathway may play a role in the inhibition of HASMC activation.

AB - Introduction: The activation of human vascular smooth muscle cell proliferation, adhesion and migration is essential for intimal hyperplasia formation. These experiments were designed to test whether zoledronic acid (ZA) would modulate indices of human smooth muscle cell activation, exert differential effects on proliferating versus quiescent cells, and determine whether these effects were dependent on GTPase binding proteins prenylation. ZA was chosen for testing in these experiments because it is clinically used in humans with cancer, and has been shown to modulate rat smooth muscle cell proliferation and migration. Methods: Human aortic smooth muscle cells (HASMC) were cultured under either proliferating or growth arrest (quiescent) conditions in the presence or absence of ZA for 48 hours, whereupon the effect of ZA on HASMC proliferation, cellular viability, metabolic activity, and membrane integrity were compared. In addition, the effect of ZA on adhesion and migration were assessed in proliferating cells. The effect of increased concentration of ZA on the mevalonate pathway and genomic/cellular stress related poly-adenosine diphosphate ribose polymerase enzyme activity were assessed using the relative prenylation of Rap-1A/B protein and the formation of poly adenosine diphosphate-ribosylated protein, respectively. Results: There was a dose dependent inhibition of cellular proliferation, adhesion and migration following ZA treatment. ZA treatment decreased indices of cellular viability and significantly increased membrane injury in proliferating versus quiescent cells. This was correlated with the appearance of unprenylated Rap-1A protein and dose dependent down regulation of activity. Conclusions: These data suggest that ZA is effective in inhibiting HASMC proliferation, adhesion, and migration, which coincide with the appearance of unprenylated RAP-1A/B protein, thereby suggesting that the mevalonate pathway may play a role in the inhibition of HASMC activation.

KW - Bisphosphonates

KW - Intimal hyperplasia

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=84877705658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877705658&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2012.10.033

DO - 10.1016/j.jss.2012.10.033

M3 - Article

C2 - 23164362

AN - SCOPUS:84877705658

VL - 182

SP - 339

EP - 346

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -